anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3&#39; cap. In some embodiments, the 3&#39; cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5&#39;-end of the aptamer and the moiety is attached the 5&#39; end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.
The present invention is a method of a non-continuous administration of a pharmaceutical to a female for a condition associated with the female&#39;s menstrual cycle, compromising in the administration of either 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid or RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. The active ingredients to be manufactured into a tablet or chewable formulation rich in cocoa flavonols such as dark chocolate no more than 65%. A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder compromising of administering to a female in need of treatment an effective amount of a compound. The first dose to be given at the onset of the premenstrual symptoms. This can be given two to four times a day up to seven days as directed. This is intended to be a short course of therapy to alleviate the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder.
The invention discloses a method for killing goat cropping insects. The method for killing goat cropping insects comprises the following operating steps: picking ripened local tomatoes, cleaning, airing, triturating to a pasty state, and smearing the triturated tomatoes on wounded parts of a goat once a day. Five days is a treatment course. By the above method, goat cropping insects can be killed effectively, and the effective rate is 93-95%. After the drug is smeared for 10 days, new fluff grows at bald spots of the goat&#39;s original fur areas. In addition, the method has no side effect. In the vast rural areas of our country, it is easy to pick tomatoes in summer. Thus, costs are low. The method is especially suitable for remote rural areas.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide surgical ring structures to support keeping a lumen of the bowel or other tubular organs to undergo anastomosis as opened for a long time.  &lt;P&gt;SOLUTION: The present disclosure provides structures 100 for deposition between adjacent intestinal sections in an anastomosis procedure. The structure 100 possesses at least an inner ring 102 of a first material, and a middle ring 104 and an outer ring 106 of a second material. The first material and the second material include a wound treatment material consisting of at least one of an adhesive, a sealant and/or a medicament. The first material is a wound treatment material different from the second material.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To produce a zinc oxide particle compsn., preferably a superfine zinc oxide particle compsn. with a high density coating comprising oxide of silicon on the surface of each particle and to obtain cosmetics contg. the compsn. SOLUTION: An aq. suspension of zinc oxide particles, preferably superfine zinc oxide particles having &lt;=0.15 μm average particle diameter is prepd., a water-soluble silicate is added to the suspension by 1-50 wt.% (expressed in terms of SiO2 ) based on the weight of zinc oxide and the suspension is neutralized to pH 6.0-8.0 by adding an acid over &gt;=40 min while keeping the temp. at a temp. of &gt;=60 deg.C. high density coatings comprising oxide of silicon are formed on the surfaces of the zinc oxide particles by 1-50 wt.% based on the weight of zinc oxide and the objective compsn. having &lt;=2 ppm (expressed in terms of Zn) solubility to pure water and &lt;=20 ppm (expressed in terms of Zn) solubility to 0.0005 wt.% aq. sulfuric acid soln. is obtd.
Especially developed for training and improving sports performance on the particular bicycle of each individual. It contains a special kinetic-resistance electronic unit 31 and 32 which precisely emulates the dynamic effect of the mass of the exercising individual at the same time as it controls the resisting torque. A mechanical system of floating shafts (spindles) 21 makes it possible to obtain full operation mode of the bicycle. Electronic sensors located in various parts send signals to the electronic control 31 which exchanges information continuously with a computer 4 or a terminal where the dynamic variables, physiological parameters and route profiles are visualized and entered, this information allowing simulation of a real competition situation and, for medical specialists, facilitating control of the athlete&#39;s performance throughout the supposed travel. Special computer programs executed from the computer 4 make it possible to combine the presentation of parameters and to generate historical records or personalized training plans which may be entered or visualized locally or remotely by another computer using a suitable modem. &lt;IMAGE&gt;
The present invention addresses the problem of providing a novel phthalocyanine dye to be used in photoimmunotherapy, a method for producing same, and a conjugate between a peptide or an antibody and said phthalocyanine dye. The present invention provides a compound represented by formula (1) or a salt thereof. (In the formula, X represents a substituent having a hydrophilic group at an end. L3, L4, L5, and L6 each independently represent a divalent linkage group. Y represents a group that can bind with an antibody or a peptide. R3 represents a substituent such as an alkyl group having 1-6 carbon atoms, an alkoxy group having 1-6 carbon atoms, a halogen atom, -SR11, -SOR12, an aryl group having 6-10 carbon atoms, -N(R13)(R14), or -NO2. If there is more than one R3, they may be identical or different from each other. &#34;s&#34; represents an integer of 0-4.)
This study will assess the efficacy of a new intradermal formulation of the trivalent inactivated influenza vaccine (TIV) compared to standard intramuscular TIV in HIV-infected men who have sex with men (MSM) in Bangkok, Thailand. Eligible participants will be randomized to receive standard full-dose intramuscular vaccine versus full-dose intradermal vaccine. Full dose (15 micrograms) intradermal TIV will be licensed for use in adult's ≥ 60 years of age in Thailand in mid-2011. In this study, intradermal TIV will be used off-label as the 15 microgram dose will be administered to individuals \&lt; 60 years of age. Efficacy of the two different formulations of influenza vaccine will be assessed by comparing immunologic responses to vaccine between the two HIV-infected study arms. Both humoral (influenza antibody) and cell-mediated (influenza- specific CD4 and CD8 T cell) immune responses will be evaluated. Humoral and cell-mediated immune responses among HIV-infected individuals with CD4 cell counts less than 200 per microliter will also be compared to immune responses in HIV-infected individuals with CD4 cell counts of 200 per microliter or greater. A small HIV-uninfected MSM control group will also be enrolled (with persons randomized into either an intramuscular or intradermal TIV arm) to serve as a comparator group for the cell-mediated immunity studies.
Immunopotentiators and antitumor agents which are nontoxic and less expensive. These immunopotentiators and antitumor agents can be obtained by using as the active ingredient an optionally purified extract of Lyophyllum decastes (Fr. Sing.) which is rich in high molecular weight polysaccharides. As this fungus, in particular, use is made of those having been artificially cultivated with the use of &#39;Kameyama No. 1&#39; as the seed culture.
PURPOSE: A functional cosmetic composition containing crude drug extract including Chamaecyparis obtuse(Siebold &amp; Zucc.) ENDL. is provided to ensure skin moisturizing and whitening effects and to reduce pore size. CONSTITUTION: A functional cosmetic composition contains crude drug extract including 40-60 wt% of Chamaecyparis obtuse(Siebold &amp; Zucc.) ENDL. The crude drug extract further contains 5-15 wt% of Chrysanthemum morifolium, 10-30 wt% of ginseng, and 10-30 wt% of Rehmanniae Radix. The crude drug extract also contains 1-5 wt% of Scutellariae Radix. The functional cosmetic composition contains 1-30 wt% of crude drug extract. The cosmetic composition is a lotion, nutrition cream, massage cream, essence, gel, serum, pack, powder, external use skin ointment, suspension, emulsion, or spray.
PURPOSE:A diuretic agent consisting of a complex of albumin with a hydrophobic loop diuretic agent. CONSTITUTION:A diuretic agent obtained by incorporating albumin (obtained by purifying directly a raw material blood plasma) with a hydrophobic loop diuretic agent (hydrophobic organic acid based diuretic agent containing furosemide, ethacrynic acid, bumetamide, etc.) at 1:1-1:5 molar ratio in a suitable solvent, e.g. sodium hydroxide reagent, physiological saline solution or phosphate-buffered saline (PBS) to give a complex, and incorporating the resultant complex therein, and having thermal stabilizing effect on albumin. The heat treatment of this albumin complex can be carried out under given conditions (60 deg.C for 10hr). In the heat treatment, the above-mentioned complex is characterized in that the amount of the given stabilizer can be reduced when the linked diuretic agent, particularly &gt;=3mol, based on the albumin, diuretic agent is present. The administration is carried out using 0.3-1mg/kg expressed in terms of the furosemide by intravenous injection.
FIELD: hygienic chemistry. SUBSTANCE: invention, in particular, relates to tooth-pastes with improved cleaning effect. Composition contains agglomerates of at least two chemically and/or physically different materials in the form of specified-size particles essentially free of organic and/or inorganic binders. Including materials having favorable therapeutic effect on teeth and gums, such as zinc citrate, has advantage of making material release from agglomerates thereby ensuring supply of material for prolonged time. Agglomerates have &#34;grain&#34; feel indicative of better cleaning and polishing of teeth. EFFECT: improved tooth cleaning. 10 cl, 12 tbl, 5 ex
This invention discloses a preparation for treating common cold. According to a definite ratio, it is made up of some raw materials including Folium Isatidis, Herba Hedyoti Diffusae, Microcos paniculata, Magnoliaceae, Microcarpaea, Moghania philippinensis. All the above raw materials are washed first, insolated by sun&#39;s rays, and then dried. After mixing agitating uniformity, they are packed finally. The preparation disclosed in this invention associated with the useful efficiency of the above Chinese herbal medicine. It has the obvious therapeutic efficiency on treatment with cold, especially with inside cold, cough and non-sweating. It can also clean out the various latent-accumulated impurities in bodily histiocytes by discharging from epidermis and feces. Otherwise, it can redress disequilibrium of human system and can form the preventive effect of cancer.
FIELD: medicine, endocrinology, pre-rehabilitation therapy. SUBSTANCE: method deals with diet and medicinal therapy along with control for patient&#39;s state of health. Additional daily hyperbaric oxygenation is conducted after an intake of mineral water and food at 2-5 seances. Then basic acidic state of capillary blood is examined and at pH value of 7.300-7.350 oxygenation is abolished to start rehabilitation therapy. EFFECT: higher efficiency of adaptation. 2 cl, 4 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for diagnosing genetic sensitivity to degenerated intervertebral disc and each kind of disease (DDD) associated with intervertebral disc degeneration; and to provide an agent or the like for preventing and treating the disease.  &lt;P&gt;SOLUTION: The method for diagnosing the genetic sensitivity to the DDD (e.g. the degenerated intervertebral disc and disc herniation) involves detecting the polymorphism present in a CILP (cartilage intermediate layer protein) gene. The prevention and treatment of the disease involves regulation (e.g. inhibition) of expression or activity of the CILP.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and a method for altering cell functions and to provide a method especially as a therapeutic treatment and/or a prophylactic treatment for neurodegenerative diseases.  &lt;P&gt;SOLUTION: The composition comprising Sel-Plex is administered under conditions in which the expression of a complement gene, the expression of a cathepsin gene, the expression of a presenilin gene or the expression of a nicastrin gene is reduced in the cerebral cortex. The composition comprising the Sel-Plex may contain sodium selenite and an antioxidant. The composition may simultaneously be administered with another Alzheimer therapeutic agent. The composition has effects on treatment or prophylaxis of Alzheimer&#39;s disease, Parkinson&#39;s disease, Huntington&#39;s disease, etc.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To obtain a curing promoter for wounds, capable of promoting treatment of the wounds causing a rupture in the skin or mucous membrane, excellent in biocompatibility and having high safety. CONSTITUTION:The curing promoter for wounds contains acidic heteropolysaccharides extracellularly secreted by a callus induced from a plant which belongs to the genus Polianthes (e.g. Polianthes tuverosa L.) as an active ingredient. The acidic heteropolysaccharides contain arabinose, mannose, galactose, glucuronic acid and xylose as constituent saccharides and the binding manner and constituent ratio thereof are expressed by the formula. The acidic heteropolysaccharides have 1X10&lt;4&gt; to 2X10&lt;7&gt; molecular weight and physicochemical properties such as solubility: soluble in water and insoluble in ethanol, ether and acetone; color reaction: positive to the allethrone reaction and carbazole reaction and negative to the Elson-Morgan reaction and specific rotatory power: [alpha]&lt;25&gt;D=0 to +20 deg. (C=1.0, aqueous solution).
Dispensing units for dispensing items, such as in a healthcare facility, are linked in a network. The dispensing units use a fingerprint to authenticate users. The fingerprints on a short list reflect recent authorization, and permit access without other identifying information. Dispensing units in the network may use different fingerprint scanning technologies, but are made compatible by enrolling fingerprints using the different technologies. Two or more reference fingerprints may be stored at a dispensing unit, permitting either a primary fingerprint or alternate fingerprint to gain access to that dispensing unit. During enrollment of a user, fingerprints for a user may be &#34;fast tracked&#34; for registration based upon a quality determination.
NEW MATERIAL:A compound shown by the formulaI(A is isothiazolyl which may have a substituent group; R is H or lower alkyl). EXAMPLE:7-( 4-Cyano-3-hydroxyisothiazole-5-yl )thioacetamido-3-( 1-methyl-tetrazole-5-yl)thiomethyl-DELTA&lt;3&gt;-cephem-4-carboxylic acid. USE:An antibacterial agent. Effective against both Gram-positive and Gram- negative bacteria. Useful as an additive for feed, preservative for food and chemical industrial products, etc. as well. PROCESS:A 7-haloacetamido-cephalosporin derivative shown by the formula II (X is halogen) or its salt is reacted with an alkali metal salt of mercaptoisothiazole which may have a substituent group at room temperature-under cooling, preferably in the presence of base, to give a compound shown by the formulaI.
Declared plant for treatment of viral hepatites using medical ozone comprises connected in series device for collection and return of patient&#39;s blood (catheter, injection needle), line of fluid flow with rate regulators, peristaltic pump, source of ozone and medical oxygen. The latter is additionally provided with two tanks, the first - for a mixture of physiological saline (PS) and heparin, and the second - with a tank of ozonized PS, mixer for mixing blood and ozonized PS with built-in filter. The peristaltic pump is equipped with control unit, and the first tank for mixture of PS and heparin is connected in the line connecting the device for taking blood from the peristaltic pump.In the first embodiment of the plant the line is connected with the mixer having built-in filter and device for return of patient’s blood. The mixer with built-in filter is connected to the second tank of ozonized PS, which is equipped with two needles, short one for injection of ozone-oxygen mixture, formed from sources of ozone and medical oxygen, and long one - for connection to the destructor.In another embodiment of the installation, the latter additionally contains a dialyzer, and tank for plasma collecting. The inlet of the inner portion of the dialyzer is connected to the outlet of the peristaltic pump, and its outlet is connected to the mixer with built-in filter. The upper inlet pipe of the outside portion of the dialyzer is connected to the source of oxygen, and lower outlet pipe of the outside portion of the dialyzer is connected to the tank for plasma collecting and then to the line, connected with the mixer with built-in filter and device for return of patient’s blood. The mixer with built-in filter is also connected with the second tank of ozonized PS, which is equipped with two needles, short one - for injection of ozone-oxygen mixture, formed from sources of ozone and medical oxygen, and long one - for connection with the destructor.In the third embodiment of the plant, the latter additionally comprises a dialyzer, and a tank for plasma collecting. The second peristaltic pump is connected to the control unit of the first peristaltic pump. In line connecting the device for blood collection with the first peristaltic pump, the first tank is connected, the lower central dialyzer pipe is connected to the first peristaltic pump, and its upper central pipe is connected to the rotary-film contactor (RFC), which is driven by an engine. The lower dialyzer pipe is connected to the tank for plasma collecting. The RFC is connected to the carbohemofilter through the second peristaltic pump, and the third RFC pipe is connected with the outlet of ozone source, which is connected to a source of medical oxygen. The upper pipe of the carbohemofilter is connected with the mixer with built-in filter and device for return of patient’s blood, and the mixer with built-in filter is also connected with the tank containing PS for supplementary heparinisation.
FIELD: chemistry. ^ SUBSTANCE: invention relates to compounds of formula (I) in form of base or a pharmaceutically acceptable addition salt with an acid. The disclosed compounds have -amyloid peptide(-A4) formation inhibiting properties. In formula (I), R1 denotes: C1-6-alkyl or phenyl; where said phenyl groups are substituted with two substitutes selected from halogen atoms; R1 and R2&#39; independently denote a hydrogen atom or a hydroxy group; R3 denotes C1-6-alkyl; one or another of radicals R4 and R5 is a group Z and one or another of radicals R4 and R5 is a -C(X)R6 group; G denotes a single bond; Y denotes a single bond, an oxygen atom, a sulphur atom, a C1-4-alkylene group; A and B independently denote a hydrogen atom, a halogen, trifluoromethyl, trifluoromethoxy group; provided that if Y denotes a single bond or an oxygen atom and if group Z is a type group, A does not denote a hydrogen atom; X denotes an oxygen atom; R6 denotes a C1-6alkoxy group. The invention also relates to a method for synthesis of formula (I) compounds, to a medicinal agent and a pharmaceutical composition based on said compounds, and to use of formula (I) compounds in preparing the medicinal agent. ^ EFFECT: increased effectiveness of using said derivatives. ^ 6 cl, 1 tbl, 31 ex
PROBLEM TO BE SOLVED: To obtain an oral preparation of ibuprofen not having an unpleasant bitter taste. SOLUTION: This oral preparation of ibuprofen not substantially contains R(-)-2-(p-isobutylphenyl)propionic acid but contains S(+)-2-(p-isobutylphenyl) propionic acid expressed by the formula. Further, by suitably blending acid component (e.g.; citric acid), a sweetening agent, an aromatizing agent, a usually used medicinal excipient, etc., the mixture is prepared to a powder preparation, a granular preparation, a liquid preparation, a chewable tablet, a foaming preparation, a troche preparation, a rapidly disintegrating solid preparation, a chewing gum preparation, etc. The dose of ibuprofen eutomer is 5-10mg in the case of infant, &gt;=1g, preferably 50-800mg for an adult as ibuprofen for one time dose to reduce a light pain. For the pain in the chronic case, 600-3200mg is administered daily by dividing it into one to several times.
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. According to the American heart association (AHA) over 19.1 million deaths worldwide in 2020 were attributed to CVD. Heart failure (HF) is considered one of the most frequent causes of hospitalization and the final stage of many heart disorders. It is associated with high rates of morbidity and mortality. Heart failure (HF) affects more than 5.8 million people in the USA and over 23 million people worldwide, making it a serious public health issue. According to the 2022 guidelines of American heart association (AHA) a variety of non-pharmacologic and pharmacologic are available to treat heart failure (HF) to prevent or reverse its symptoms. Nonpharmacologic treatments may involve dietary sodium and fluid restriction, proper physical activity, and attention to weight gain depending on the illness\&#39;s severity. Pharmacologic treatments include the use of diuretics, vasodilators, inotropic agents, anticoagulants, beta blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), digoxin, nitrates, B-type natriuretic peptides (BNPs), I(f) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), soluble guanylate cyclase stimulators, sodium-glucose cotransporter-2 inhibitors (SGLT2Is), and mineralocorticoid receptor antagonists (MRAs). Recent study has shown that SGLT2I not only lowers blood sugar levels but also protects the kidney and heart, which can dramatically lower cardiovascular events, stall the advancement of renal failure, significantly raise patient quality of life, and lower medical costs for families and society. A study showed that Empagliflozin has cardio-renal protective effects as it reduced inflammatory and fibrotic markers, such as NF-κB, TGF-β1, and improved fibrosis. However, it was found that the variation in treatment response with SGLT2I may be due to the genetic polymorphism of TGF-β1 since this polymorphism may influence its expression. Therefore, it is important to assess the implications of genetic variants of the TGF-β1 gene in patients with HFrEF and the association of this polymorphism with treatment response to SGLT2I. Therefore, by correlating the pharmacogenetics hand in hand with the mechanistic markers involved in the pathogenesis of HF, this can aid in the development of individualized, therapeutic strategies and improve the patient's drug response.